Wolverine Trading’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $45.9M | Buy |
81,900
+11,900
| +17% | +$6.73M | 0.03% | 343 |
|
|
2025
Q2 | $36.5M | Buy |
70,000
+17,000
| +32% | +$9.49M | 0.04% | 303 |
|
|
2025
Q1 | $33.8M | Buy |
53,000
+4,400
| +9% | +$3.03M | 0.04% | 282 |
|
|
2024
Q4 | $34.1M | Buy |
48,600
+9,600
| +25% | +$8.06M | 0.03% | 320 |
|
|
2024
Q3 | $40.7M | Buy |
39,000
+13,800
| +55% | +$15.4M | 0.04% | 250 |
|
|
2024
Q2 | $26.5M | Buy |
25,200
+6,400
| +34% | +$6.2M | 0.03% | 324 |
|
|
2024
Q1 | $18.1M | Sell |
18,800
-3,700
| -16% | -$3.52M | 0.02% | 439 |
|
|
2023
Q4 | $19.8M | Buy |
22,500
+3,100
| +16% | +$2.55M | 0.02% | 454 |
|
|
2023
Q3 | $16M | Sell |
19,400
-23,400
| -55% | -$18.4M | 0.02% | 459 |
|
|
2023
Q2 | $30.3M | Buy |
+42,800
| New | +$33M | 0.04% | 258 |
|
|
2023
Q1 | – | Sell |
-23,200
| Closed | -$16.7M | – | 4813 |
|
|
2022
Q4 | $16.7M | Hold |
23,200
| – | – | 0.03% | 446 |
|
|
2022
Q3 | $16.1M | Buy |
23,200
+3,800
| +20% | +$2.39M | 0.03% | 386 |
|
|
2022
Q2 | $11.6M | Buy |
19,400
+4,500
| +30% | +$2.93M | 0.02% | 462 |
|
|
2022
Q1 | $10.3M | Sell |
14,900
-16,200
| -52% | -$10.2M | 0.01% | 682 |
|
|
2021
Q4 | $20M | Sell |
31,100
-9,400
| -23% | -$5.78M | 0.02% | 471 |
|
|
2021
Q3 | $24.6M | Buy |
40,500
+800
| +2% | +$497K | 0.03% | 447 |
|
|
2021
Q2 | $21.7M | Buy |
39,700
+9,200
| +30% | +$4.66M | 0.03% | 387 |
|
|
2021
Q1 | $14.4M | Sell |
30,500
-62,600
| -67% | -$30.5M | 0.02% | 531 |
|
|
2020
Q4 | $44.5M | Buy |
93,100
+37,900
| +69% | +$20.5M | 0.07% | 185 |
|
|
2020
Q3 | $31.7M | Sell |
55,200
-6,500
| -11% | -$3.94M | 0.08% | 181 |
|
|
2020
Q2 | $37.7M | Buy |
+61,700
| New | +$35M | 0.1% | 115 |
|
|
2020
Q1 | – | Sell |
-98,300
| Closed | -$36.7M | – | 5145 |
|
|
2019
Q4 | $36.7M | Sell |
98,300
-5,300
| -5% | -$1.78M | 0.09% | 170 |
|
|
2019
Q3 | $28.3M | Buy |
+103,600
| New | +$30.7M | 0.08% | 190 |
|
|
2019
Q1 | – | Sell |
-61,600
| Closed | -$22.3M | – | 5158 |
|
|
2018
Q4 | $22.3M | Buy |
61,600
+6,600
| +12% | +$2.42M | 0.06% | 225 |
|
|
2018
Q3 | $22.2M | Sell |
55,000
-2,900
| -5% | -$1.1M | 0.05% | 268 |
|
|
2018
Q2 | $19.9M | Hold |
57,900
| – | – | 0.05% | 256 |
|
|
2018
Q1 | $19.9M | Sell |
57,900
-26,500
| -31% | -$9.22M | 0.05% | 256 |
|
|
2017
Q4 | $31.7M | Buy |
84,400
+8,700
| +11% | +$3.52M | 0.11% | 146 |
|
|
2017
Q3 | $33.8M | Buy |
+75,700
| New | +$36M | 0.13% | 125 |
|
|
2017
Q2 | – | Sell |
-61,900
| Closed | -$23.9M | – | 4851 |
|
|
2017
Q1 | $23.9M | Buy |
61,900
+30,400
| +97% | +$11.3M | 0.13% | 147 |
|
|
2016
Q4 | $11.6M | Sell |
31,500
-100
| -0.3% | -$38K | 0.06% | 348 |
|
|
2016
Q3 | $12.8M | Sell |
31,600
-5,300
| -14% | -$2.13M | 0.06% | 366 |
|
|
2016
Q2 | $12.8M | Buy |
+36,900
| New | +$14.2M | 0.07% | 277 |
|
Other funds holding REGN
Wolverine Trading's REGN Position: Q3 2025 in Review
Wolverine Trading increased its Regeneron Pharmaceuticals (REGN) stake by 54% in Q3 2025, buying an estimated $5.98M and bringing the position to 30,161 shares worth $16.9M. The position accounts for 0.01% of the portfolio, ranked #664.
Wolverine Trading first reported a position in REGN in Q4 2016 and has held it in 24 quarters since. The position peaked at $39.8M in Q4 2022. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.
- Wolverine Trading held 30,161 shares of Regeneron Pharmaceuticals worth $16.9M as of Q3 2025.
- Wolverine Trading bought 10,583 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $5.98M.
- Regeneron Pharmaceuticals made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #664 holding.
- Wolverine Trading first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 24 quarters since.
- Wolverine Trading's Regeneron Pharmaceuticals position peaked at $39.8M in Q4 2022.
- 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.